By Puyaan Singh and Sahil Pandey
(Reuters) -Labcorp forecast lower annual revenue growth for its contract research unit on Tuesday, as a prolonged funding crunch continues to weigh on its early-stage drug development clients.
Contract research firms have witnessed reduced spending from biotech clients in the past two years. The funding crunch, which was expected to improve this year, could be prolonged due to policy uncertainty from the Trump administration.
“The issue that we’re seeing is with timing of study starts … We expected that to start to come back to more normalcy,” CEO Adam Schechter said during a call with analysts.
The comments on continued pressure on the unit weighed on shares, which were down 5.5% in afternoon trading, despite the company raising its annual profit forecast and reporting better-than-expected third-quarter earnings.
While the…



